Morgan Stanley
BRNS

Morgan Stanley’s Barinthus Biotherapeutics BRNS Stock Holding History

Morgan Stanley’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.8K Buy
108,843
+106,633
+4,825% +$69.5K ﹤0.01% 6376
2026
Q1 		$1.26K Sell
2,210
-1,196
-35% -$788 ﹤0.01% 7398
2025
Q4 		$2.38K Sell
3,406
-1,536
-31% -$1.53K ﹤0.01% 7211
2025
Q3 		$6.18K Buy
4,942
+90
+2% +$113 ﹤0.01% 7037
2025
Q2 		$4.51K Buy
4,852
+3,981
+457% +$3.48K ﹤0.01% 7065
2025
Q1 		$847 Sell
871
-7,150
-89% -$7.34K ﹤0.01% 7305
2024
Q4 		$9.69K Sell
8,021
-3,962
-33% -$4.61K ﹤0.01% 6815
2024
Q3 		$14.3K Buy
11,983
+3,110
+35% +$4.17K ﹤0.01% 6609
2024
Q2 		$12.4K Sell
8,873
-3,989
-31% -$9.01K ﹤0.01% 6602
2024
Q1 		$30.6K Sell
12,862
-3,605
-22% -$10.2K ﹤0.01% 6372
2023
Q4 		$60.8K Sell
16,467
-4,748
-22% -$16K ﹤0.01% 6097
2023
Q3 		$65.6K Buy
21,215
+5,768
+37% +$12.4K ﹤0.01% 6050
2023
Q2 		$31.8K Sell
15,447
-53,350
-78% -$126K ﹤0.01% 6384
2023
Q1 		$154K Buy
68,797
+56,982
+482% +$159K ﹤0.01% 5827
2022
Q4 		$27.8K Sell
11,815
-753
-6% -$1.92K ﹤0.01% 6546
2022
Q3 		$40K Sell
12,568
-1,241
-9% -$5.27K ﹤0.01% 6498
2022
Q2 		$61K Buy
13,809
+4,511
+49% +$21.7K ﹤0.01% 6519
2022
Q1 		$48K Sell
9,298
-333
-3% -$2.68K ﹤0.01% 6719
2021
Q4 		$107K Sell
9,631
-14,443
-60% -$182K ﹤0.01% 6399
2021
Q3 		$379K Buy
24,074
+7,193
+43% +$109K ﹤0.01% 5659
2021
Q2 		$284K Buy
+16,881
New +$250K ﹤0.01% 5844

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley's BRNS Position: Q2 2026 in Review

Morgan Stanley increased its Barinthus Biotherapeutics (BRNS) stake by 4,825% in Q2 2026, buying an estimated $69.5K and bringing the position to 108,843 shares worth $71.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6376.

Morgan Stanley first reported a position in BRNS in Q2 2021 and has held it in 21 quarters since. The position peaked at $379K in Q3 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

  • Morgan Stanley held 108,843 shares of Barinthus Biotherapeutics worth $71.8K as of Q2 2026.
  • Morgan Stanley bought 106,633 Barinthus Biotherapeutics shares in Q2 2026, an estimated $69.5K.
  • Barinthus Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6376 holding.
  • Morgan Stanley first reported a position in Barinthus Biotherapeutics in Q2 2021 and has held it in 21 quarters since.
  • Morgan Stanley's Barinthus Biotherapeutics position peaked at $379K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.